Berlin, 2 January. German Chancellor Olaf Scholz pledged to improve conditions in the research sector in Germany during a visit to the Marburg (centre) site of biotech company BioNTech today.
After BioNTech recently announced that it was moving some of its research work to Britain, Scholz said, “We will do everything possible to improve the legal framework so that everything can be done quickly and quickly in Germany.” Could.”
The External Affairs Minister pointed out that it is necessary to remove barriers hindering research work, work with patients and use the data obtained and stressed the importance of “stabilising” the research landscape in the country.
“If it has been possible to set a new pace for infrastructure construction in Germany and to build a gas pipeline and terminal in 200 days, it is possible to set a similar pace for the science and research sector,” Scholz said.
However, the chancellor insisted that BioNTech does not need “convincing” to leave Germany, as the biotech company, which developed the first vaccine approved against COVID-19, has a major “commitment” to the country.
For his part, BioNTech co-founder Özlem Türeci was pleased that the production of plasmids, circular DNA molecules that are a central component in manufacturing vaccines using mRNA, will start soon in Marburg.
It is a move of “strategic relevance” for Germany as a biotechnological location and which will also allow progress in the manufacture of cancer vaccines that the company is conducting clinical trials.